In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2

Lamia Abd Al Kader, Takashi Oka, Katsuyoshi Takata, Xu Sun, Hiaki Sato, Ichiro Murakami, Tomohiro Toji, Akihiro Manabe, Hiroshi Kimura, Tadashi Yoshino

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ cancers, while Mel-18/PCGF2 has been reported as a tumor suppressor. Detailed expression profiles of PcG proteins and their diagnostic significance in malignant lymphomas are still unknown. In this study, we analyzed the expression levels of Ezh2, Bmi-1, Mel-18, and Ki67 in 197 Hodgkin's and non-Hodgkin's lymphoma patient samples and in lymphoma cell lines using immunohistochemistry, fluorescent immunocytochemistry, and Western blotting. Immunohistochemical staining showed that Ezh2 expression was significantly increased in aggressive compared to indolent subtypes of B cell neoplasms (P = 0.000-0.030), while no significant differences in Bmi-1 expression were found between these subtypes. Compared to the normal counterpart, T cell lymphomas showed significant overexpression of Bmi-1 (P = 0.011) and Ezh2 (P = 0.000). The Ki67 labeling index showed a positive correlation with Ezh2 expression in B cell lymphomas (correlation coefficient (Co) = 0.983, P = 0.000) and T/NK cell lymphomas (Co = 0.629, P = 0.000). Fluorescent immunohistochemical staining showed coexpression of Ezh2 and Ki67 in the same tumor cells, indicating that Ezh2 expression correlates with cell proliferation. Both B and T/NK cell neoplasms showed low expression of Mel-18 and high expression of both Bmi-1 and Ezh2. In conclusion, in aggressive lymphoma variants, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Coexpression of Bmi-1 and Ezh2 is a characteristic of aggressive lymphomas. Ezh2 correlates with the proliferation and aggressive nature of non-Hodgkin's lymphomas.

Original languageEnglish
Pages (from-to)697-711
Number of pages15
JournalVirchows Archiv
Volume463
Issue number5
DOIs
Publication statusPublished - Nov 2013

Fingerprint

Non-Hodgkin's Lymphoma
Lymphoma
Polycomb-Group Proteins
T-Cell Lymphoma
Neoplasms
Natural Killer Cells
Enhancer of Zeste Homolog 2 Protein
Immunohistochemistry
Staining and Labeling
Hematopoiesis
Gene Silencing
B-Cell Lymphoma
Hodgkin Disease
Chromatin
Cell Cycle
B-Lymphocytes
Western Blotting
Cell Proliferation
Cell Line

Keywords

  • Bmi-1
  • Ezh2
  • Malignant lymphoma
  • Mel-18
  • PRC1.2
  • PRC1.4

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Cell Biology
  • Molecular Biology

Cite this

In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. / Abd Al Kader, Lamia; Oka, Takashi; Takata, Katsuyoshi; Sun, Xu; Sato, Hiaki; Murakami, Ichiro; Toji, Tomohiro; Manabe, Akihiro; Kimura, Hiroshi; Yoshino, Tadashi.

In: Virchows Archiv, Vol. 463, No. 5, 11.2013, p. 697-711.

Research output: Contribution to journalArticle

Abd Al Kader, Lamia ; Oka, Takashi ; Takata, Katsuyoshi ; Sun, Xu ; Sato, Hiaki ; Murakami, Ichiro ; Toji, Tomohiro ; Manabe, Akihiro ; Kimura, Hiroshi ; Yoshino, Tadashi. / In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. In: Virchows Archiv. 2013 ; Vol. 463, No. 5. pp. 697-711.
@article{8541b0de747245bda0532c86110f2386,
title = "In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2",
abstract = "Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ cancers, while Mel-18/PCGF2 has been reported as a tumor suppressor. Detailed expression profiles of PcG proteins and their diagnostic significance in malignant lymphomas are still unknown. In this study, we analyzed the expression levels of Ezh2, Bmi-1, Mel-18, and Ki67 in 197 Hodgkin's and non-Hodgkin's lymphoma patient samples and in lymphoma cell lines using immunohistochemistry, fluorescent immunocytochemistry, and Western blotting. Immunohistochemical staining showed that Ezh2 expression was significantly increased in aggressive compared to indolent subtypes of B cell neoplasms (P = 0.000-0.030), while no significant differences in Bmi-1 expression were found between these subtypes. Compared to the normal counterpart, T cell lymphomas showed significant overexpression of Bmi-1 (P = 0.011) and Ezh2 (P = 0.000). The Ki67 labeling index showed a positive correlation with Ezh2 expression in B cell lymphomas (correlation coefficient (Co) = 0.983, P = 0.000) and T/NK cell lymphomas (Co = 0.629, P = 0.000). Fluorescent immunohistochemical staining showed coexpression of Ezh2 and Ki67 in the same tumor cells, indicating that Ezh2 expression correlates with cell proliferation. Both B and T/NK cell neoplasms showed low expression of Mel-18 and high expression of both Bmi-1 and Ezh2. In conclusion, in aggressive lymphoma variants, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Coexpression of Bmi-1 and Ezh2 is a characteristic of aggressive lymphomas. Ezh2 correlates with the proliferation and aggressive nature of non-Hodgkin's lymphomas.",
keywords = "Bmi-1, Ezh2, Malignant lymphoma, Mel-18, PRC1.2, PRC1.4",
author = "{Abd Al Kader}, Lamia and Takashi Oka and Katsuyoshi Takata and Xu Sun and Hiaki Sato and Ichiro Murakami and Tomohiro Toji and Akihiro Manabe and Hiroshi Kimura and Tadashi Yoshino",
year = "2013",
month = "11",
doi = "10.1007/s00428-013-1428-y",
language = "English",
volume = "463",
pages = "697--711",
journal = "Virchows Archiv",
issn = "0945-6317",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - In aggressive variants of non-Hodgkin lymphomas, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2

AU - Abd Al Kader, Lamia

AU - Oka, Takashi

AU - Takata, Katsuyoshi

AU - Sun, Xu

AU - Sato, Hiaki

AU - Murakami, Ichiro

AU - Toji, Tomohiro

AU - Manabe, Akihiro

AU - Kimura, Hiroshi

AU - Yoshino, Tadashi

PY - 2013/11

Y1 - 2013/11

N2 - Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ cancers, while Mel-18/PCGF2 has been reported as a tumor suppressor. Detailed expression profiles of PcG proteins and their diagnostic significance in malignant lymphomas are still unknown. In this study, we analyzed the expression levels of Ezh2, Bmi-1, Mel-18, and Ki67 in 197 Hodgkin's and non-Hodgkin's lymphoma patient samples and in lymphoma cell lines using immunohistochemistry, fluorescent immunocytochemistry, and Western blotting. Immunohistochemical staining showed that Ezh2 expression was significantly increased in aggressive compared to indolent subtypes of B cell neoplasms (P = 0.000-0.030), while no significant differences in Bmi-1 expression were found between these subtypes. Compared to the normal counterpart, T cell lymphomas showed significant overexpression of Bmi-1 (P = 0.011) and Ezh2 (P = 0.000). The Ki67 labeling index showed a positive correlation with Ezh2 expression in B cell lymphomas (correlation coefficient (Co) = 0.983, P = 0.000) and T/NK cell lymphomas (Co = 0.629, P = 0.000). Fluorescent immunohistochemical staining showed coexpression of Ezh2 and Ki67 in the same tumor cells, indicating that Ezh2 expression correlates with cell proliferation. Both B and T/NK cell neoplasms showed low expression of Mel-18 and high expression of both Bmi-1 and Ezh2. In conclusion, in aggressive lymphoma variants, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Coexpression of Bmi-1 and Ezh2 is a characteristic of aggressive lymphomas. Ezh2 correlates with the proliferation and aggressive nature of non-Hodgkin's lymphomas.

AB - Polycomb group (PcG) proteins are important for the regulation of hematopoiesis by regulating chromatin compaction and silencing genes related to differentiation and cell cycle. Overexpression of enhancer of zeste homologue 2 (Ezh2) and Bmi-1/PCGF4 has been implicated in solid organ cancers, while Mel-18/PCGF2 has been reported as a tumor suppressor. Detailed expression profiles of PcG proteins and their diagnostic significance in malignant lymphomas are still unknown. In this study, we analyzed the expression levels of Ezh2, Bmi-1, Mel-18, and Ki67 in 197 Hodgkin's and non-Hodgkin's lymphoma patient samples and in lymphoma cell lines using immunohistochemistry, fluorescent immunocytochemistry, and Western blotting. Immunohistochemical staining showed that Ezh2 expression was significantly increased in aggressive compared to indolent subtypes of B cell neoplasms (P = 0.000-0.030), while no significant differences in Bmi-1 expression were found between these subtypes. Compared to the normal counterpart, T cell lymphomas showed significant overexpression of Bmi-1 (P = 0.011) and Ezh2 (P = 0.000). The Ki67 labeling index showed a positive correlation with Ezh2 expression in B cell lymphomas (correlation coefficient (Co) = 0.983, P = 0.000) and T/NK cell lymphomas (Co = 0.629, P = 0.000). Fluorescent immunohistochemical staining showed coexpression of Ezh2 and Ki67 in the same tumor cells, indicating that Ezh2 expression correlates with cell proliferation. Both B and T/NK cell neoplasms showed low expression of Mel-18 and high expression of both Bmi-1 and Ezh2. In conclusion, in aggressive lymphoma variants, Ezh2 is strongly expressed and polycomb repressive complex PRC1.4 dominates over PRC1.2. Coexpression of Bmi-1 and Ezh2 is a characteristic of aggressive lymphomas. Ezh2 correlates with the proliferation and aggressive nature of non-Hodgkin's lymphomas.

KW - Bmi-1

KW - Ezh2

KW - Malignant lymphoma

KW - Mel-18

KW - PRC1.2

KW - PRC1.4

UR - http://www.scopus.com/inward/record.url?scp=84889080811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889080811&partnerID=8YFLogxK

U2 - 10.1007/s00428-013-1428-y

DO - 10.1007/s00428-013-1428-y

M3 - Article

C2 - 23948956

AN - SCOPUS:84889080811

VL - 463

SP - 697

EP - 711

JO - Virchows Archiv

JF - Virchows Archiv

SN - 0945-6317

IS - 5

ER -